The DOI matches its Crossref record.
Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors
Abstract
BACKGROUND: The frequency of subsequent testicular cancer (referred to as metachronous testicular cancer) in men who have had previous testicular cancer is relatively high. The rate of metachronous testicular cancer in men with extragonadal germ cell tumors (EGCTs), however, is largely unknown. We conducted a retrospective study of EGCT patients to determine the incidence, cumulative risk, and specific risk factors for metachronous testicular cancers. METHODS: A standardized questionnaire about patient characteristics, the extent of EGCT disease, any second malignancies, and treatments received was completed for 635 patients with EGCTs identified from the medical records of 11 cancer centers in Europe and the United States from 1975 through 1996. Comparisons with age group-specific data from the Saarland, Germany, population-based cancer registry were used to calculate the standardized incidence ratio (SIR). The Kaplan-Meier method was used to analyze survival data and cumulative risk. All statistical tests were two-sided. RESULTS: Sixteen EGCT patients (4.1%) developed metachronous testicular cancers, with a median time between diagnoses of 60 months (range, 14-102 months). The risk of developing metachronous testicular cancers was statistically significantly increased in patients with EGCTs (observed = 16; expected = 0.26; SIR = 62; 95% confidence interval [CI] = 36 to 99) and in subsets of EGCT patients with mediastinal location (SIR = 31; 95% CI = 8 to 59), retroperitoneal location (SIR = 100; 95% CI = 54 to 172), and nonseminomatous histology (SIR = 75; 95% CI = 43 to 123). The cumulative risk of developing a metachronous testicular cancer 10 years after a diagnosis of EGCT was 10.3% (95% CI = 4.9% to 15.6%) and was higher among patients with nonseminomatous EGCTs (14.3%; 95% CI = 6.7% to 21.9%) and retroperitoneal EGCTs (14.2%; 95% CI = 5.6% to 22.8%) than among patients with seminomatous EGCTs (1.4%; 95% CI = 0.0% to 4.2%) and mediastinal EGCTs (6.2%; 95% CI = 0.1% to 12.2%). CONCLUSIONS: Patients with EGCTs, particularly those with retroperitoneal or nonseminomatous tumors, but also those with primary mediastinal EGCTs, are at an increased risk of metachronous testicular cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- Hartmann, 1999, Drugs, 58, 257, 10.2165/00003495-199958020-00004 · doi:10.2165/00003495-199958020-00004
- Bosl, 1997, New England Journal of Medicine, 337, 242, 10.1056/NEJM199707243370406 · DOI · Paper page
- Osterlind, 1991, JNCI Journal of the National Cancer Institute, 83, 1391, 10.1093/jnci/83.19.1391 · doi:10.1093/jnci/83.19.1391
- Dieckmann, 1996, Journal of Clinical Oncology, 14, 3126, 10.1200/JCO.1996.14.12.3126 · doi:10.1200/jco.1996.14.12.3126
- Daugaard, 1987, Lancet, 2, 528, 10.1016/S0140-6736(87)92922-9 · doi:10.1016/s0140-6736(87)92922-9
- Hailemariam, 1997, Cancer, 79, 1031, 10.1002/(SICI)1097-0142(19970301)79:5<1031::AID-CNCR21>3.0.CO;2-1 · doi:10.1002/(sici)1097-0142(19970301)79:5<1031::aid-cncr21>3.0.co;2-1
- Lokich, 1994, Cancer investigation, 12, 406, 10.3109/07357909409038232 · doi:10.3109/07357909409038232
- 2000, Urology, 55, 949
- Hayashi, 1996, Urologia internationalis, 57, 194, 10.1159/000282911 · doi:10.1159/000282911
- Gonz lez Quintela, 1991, European urology, 19, 336, 10.1159/000473655 · doi:10.1159/000473655
- Gerl, 1996, Cancer, 77, 526, 10.1002/(SICI)1097-0142(19960201)77:3<526::AID-CNCR15>3.0.CO;2-6 · doi:10.1002/(sici)1097-0142(19960201)77:3<526::aid-cncr15>3.0.co;2-6
- Dueland, 1998, British Journal of Cancer, 77, 329, 10.1038/bjc.1998.51 · doi:10.1038/bjc.1998.51
- 2001, Urologic oncology, 6, 41
- 1987, IARC scientific publications, 82, 1
- 1958, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
- 1972, J R STAT SOC SER B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x · DOI · Paper page
- Asif, 1968, The Journal of urology, 99, 776, 10.1016/S0022-5347(17)62792-7 · doi:10.1016/s0022-5347(17)62792-7
- Cox, 1975, Cancer, 36, 1162, 10.1002/1097-0142(197509)36:3<1162::AID-CNCR2820360351>3.0.CO;2-0 · doi:10.1002/1097-0142(197509)36:3<1162::aid-cncr2820360351>3.0.co;2-0
- Luna, 1976, American Journal of Clinical Pathology, 65, 450, 10.1093/ajcp/65.4.450 · DOI
- Hartmann, 2000, Cancer, 88, 2629, 10.1002/1097-0142(20000601)88:11<2629::AID-CNCR27>3.0.CO;2-F · doi:10.1002/1097-0142(20000601)88:11<2629::aid-cncr27>3.0.co;2-f
- Christensen, 1998, Annals of Oncology, 9, 657, 10.1023/A:1008213515649 · doi:10.1023/a:1008213515649
- Hartmann, 2000, JNCI Journal of the National Cancer Institute, 92, 54, 10.1093/jnci/92.1.54 · DOI · Paper page
Cited by
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Ståhl, E., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.12.024 · Cited by 617
Self-citationSchmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
Self-citationBokemeyer, C., Nichols, C. R., Droz, J.-P., Schmoll, H.-J., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Kanz, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.062 · Cited by 503
Self-citationImproved survival in women with BRCA‐associated ovarian carcinoma
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A., & Karlan, B. Y. (2003) · Cancer · doi:10.1002/cncr.11310 · Cited by 433
Metadata
- Authors
- Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Beyer, J., Pont, J., Fizazi, K., Hecker, H., Kanz, L., Einhorn, L., & Bokemeyer, C.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-11-21
- Volume
- 93
- Issue
- 22
- Pages
- 1733-1738
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2127405017
- Cited by
- 162
- References
- 0
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. https://app.cochat.ai/papers/10.1093/jnci/93.22.1733
- The paper
- Hartmann, J. T., Fossa, S. D., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Beyer, J., Pont, J., Fizazi, K., Hecker, H., Kanz, L., Einhorn, L., & Bokemeyer, C. (2001). Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/93.22.1733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.